Clinical trials: Antibody
Meningoccocal Disease
Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
- Trial name
- PERS-ACYWX-03 (NCT07379151)
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Systemic Lupus Erythematosus
Belimumab Assessment of Safety in SLE
The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE).
- Trial name
- BASE (NCT01705977)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 250 sites in United States, Argentina and 31 more
- Volunteers
- 4,019 people
- Sponsor
- GlaxoSmithKline
Celiac Disease, Celiac Sprue
Antibody Treatment for Advanced Celiac Disease
Background: Celiac disease is a condition where the immune system attacks the cells of the small intestine. The intestine becomes inflamed and cannot digest food properly.
- Conditions
- Celiac Disease, Celiac Sprue, Gluten Enteropathy, Gluten-Sensitive Enteropathy
- Trial name
- NCT01893775
- Testing
- Hu-Mik- Beta-1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002681
- Testing
- aldesleukin, daclizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roger Williams Medical Center
Anemia
BioRBC Survival in Adults With Prior Antibody Response to BioRBCs
Objective: To gather safety and efficacy BioRBC data from adult subjects who previously developed transient BioRBC antibody responses by redosing them and observing for adverse clinical or laboratory (i.e., a positive BioRBC…
- Trial name
- NCT02077751
- Testing
- biotin labelled RBCs
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- John A Widness
B Cell Lymphoma, Follicular Lymphoma
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic…
- Conditions
- B Cell Lymphoma, Follicular Lymphoma, Lymphoma
- Trial name
- NCT00001512
- Testing
- Id-KLH Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Ankylosing Spondylitis
Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis
- Trial name
- NCT00195819
- Testing
- adalimumab (D2E7)
- Where
- 9 sites in Canada
- Volunteers
- 82 people
- Sponsor
- Abbott
Moderate to Severe Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05761028
- Testing
- CM310
- Where
- China
- Volunteers
- 600 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Metastatic Malignant Neoplasm
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response.
- Trial name
- NCT06240728
- Testing
- NPX887
- Where
- 8 sites in United States, South Korea
- Volunteers
- 144 people
- Sponsor
- NextPoint Therapeutics, Inc.
Primary Immune Deficiency, Secondary Immune Deficiency
Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules
The purpose of the study is to assess the impact of immunoglobulin treatment by subcutaneous injections every 2 weeks (biweekly) on a cohort of patients with primary and secondary immune deficiencies.
- Trial name
- NCT02711228
- Testing
- Subcutaneous Immune Globulin (Human) (Hizentra)
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- CSL Behring
IgA Nephropathy
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin…
- Trial name
- NCT05775042
- Testing
- CM338
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Keymed Biosciences Co.Ltd
Neuroendocrine Tumors
Study of JS001 in Patients With Advanced Neuroendocrine Tumors
This is a multi-center, open-label, phase Ib study evaluating safety and efficacy of the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with neuroendocrine tumors who have failed in previous systemic treatment.
- Trial name
- NCT03167853
- Testing
- humanized anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Diphtheria, Tetanus
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
This is a follow-up of Study A3L11 (NCT00404651). Immunogenicity To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP~T or Infanrix hexa™.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00654901
- Testing
- DTaP-IPV-Hep B-PRP~T vaccine (Batch 1), DTaP-IPV-Hep B-PRP~T vaccine (Batch 2), DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)
- Where
- 4 sites in Mexico
- Volunteers
- 881 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Metastatic Urothelial Cell Cancer
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
This is a single arm, open-label phase Ib study of combining eribulin mesylate with avelumab. The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.
- Trial name
- NCT03502681
- Testing
- Eribulin Mesylate, Avelumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Monika Joshi, MD
Non-Small Cell Lung Cancer
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
The main objective of this study was to evaluate the anti-tumor activity of gimistotug (BGB-A445) plus investigational agents in participants with non-small cell lung cancer (NSCLC).
- Trial name
- NCT06029127
- Testing
- Gimistotug, Docetaxel, BGB-15025
- Where
- 18 sites in China, South Korea
- Volunteers
- 35 people
- Sponsor
- BeiGene
Cow's Milk Allergy
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms…
- Trial name
- APTITUDE (NCT04492683)
- Testing
- DBV1605
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- DBV Technologies
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Psoriasis
International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque psoriasis, in whom poor response to previous…
- Trial name
- NCT02762994
- Testing
- BCD-085
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biocad
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4)…
- Trial name
- NCT01892345
- Testing
- Eculizumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 143 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.